Videos
Biopharma Trends & CDMOs
Biopharma Trends & CDMOs
Steve King of iBio discusses biopharma trends impacting CDMOs and the opportunities they present
06.26.19
Earlier in June, iBio introduced its cGMP sterile fill-finish capabilities for pharmaceutical products, including monoclonal antibodies, viral vectors and other biologics at its 135,000 square foot CDMO facility in Bryan, TX. iBio recently initiated its new operation with the signing of a supply agreement with a clinical-stage biopharmaceutical company developing gene and cell therapies.
Under the supply agreement, iBio will formulate and fill clinical research quantities of one of the customer’s investigational therapies into sterile vials for use in a planned late-stage clinical trial.
Under the supply agreement, iBio will formulate and fill clinical research quantities of one of the customer’s investigational therapies into sterile vials for use in a planned late-stage clinical trial.
Related Searches:
